Reducing the regulatory burden of plant biotechnology regulations in Canada

Regulations within the crop agriculture industry exist to ensure that products undergoing risk assessment prior to commercialization are safe for the environment and human consumption. Since 1995, these regulations have provided safe crops and foods for Canadians to consume, as no commercialized innovative product has caused any post-commercialization health or environmental problems. However, Canada suffers from a gap in its innovation pipeline in that far more investments go into the innovation pipeline than products come out. Canada is a global top ten nation in terms of innovation investments yet drops over ten positions when it comes to outputs. Additionally, Canada is one of the lowest ranked on the G30 list of countries in terms of regulatory burden on the economy. This article describes updates to the regulatory framework for plant biotechnology, highlighting recent changes regarding regulation of gene editing technologies and how these changes respond to previously identified innovation barriers.

Authors

Institutions

Publication Details

Journal
Genome
Published
2025-01-01
DOI
https://doi.org/10.1139/gen-2024-0164
Citations
4
Primary Topic
Genetically Modified Organisms Research
Type
article
Field-Weighted Citation Impact
7.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Reducing the regulatory burden of plant biotechnology regulations in Canada

Simona Lubieniechi, Savannah Gleim, Stuart Smyth
4 citations
Genome
Genetically Modified Organisms Research
7.00
article

Reducing the regulatory burden of plant biotechnology regulations in Canada

Simona Lubieniechi, Savannah Gleim, Stuart Smyth
article en
4 citations

Abstract

Regulations within the crop agriculture industry exist to ensure that products undergoing risk assessment prior to commercialization are safe for the environment and human consumption. Since 1995, these regulations have provided safe crops and foods for Canadians to consume, as no commercialized innovative product has caused any post-commercialization health or environmental problems. However, Canada suffers from a gap in its innovation pipeline in that far more investments go into the innovation pipeline than products come out. Canada is a global top ten nation in terms of innovation investments yet drops over ten positions when it comes to outputs. Additionally, Canada is one of the lowest ranked on the G30 list of countries in terms of regulatory burden on the economy. This article describes updates to the regulatory framework for plant biotechnology, highlighting recent changes regarding regulation of gene editing technologies and how these changes respond to previously identified innovation barriers.

GenomeVol. 68
University of Saskatchewan (CA)
Openalex Percentile: Top 4%
Genetically Modified Organisms Research
7.00
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Reducing the regulatory burden of plant biotechnology regulations in Canada — Simona Lubieniechi, Savannah Gleim, et al. · Genome (2025) | TGRS Research Map | TGRS